Partner
Ryan O'Quinn, Ph.D., maintains a versatile practice focusing on U.S. district court patent litigation, post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), patent prosecution, and portfolio management and counseling.
Ryan's practice covers a range of technologies, including pharmaceuticals, biotechnology, immunotherapy, medical devices, computer software, business methods, vending technologies, and mechanical systems. He has litigation and counseling experience in small molecule drugs, biologics, and nucleic acid compositions.
Prior to joining Finnegan, Ryan conducted doctoral and undergraduate research in cellular and molecular biology and biomedical engineering. His research, including work at the National Institutes of Health (NIH) and the Marine Biological Laboratory at Woods Hole, focused on advanced microscopy techniques and molecular mechanisms regulating cell division. Ryan previously served as an adjunct professor at George Washington University Law School in the Scholarly Writing Program, where he supervised student members of the Federal Circuit Bar Journal. He has participated as a panel advisor during the Pitch Rounds competition of the Southeast BIO (SEBIO) Annual Life Sciences Venture Capital Conference. Ryan also served as an advisor to the Southeast Life Sciences (SLSA) ADVANSE Virtual Pitch Rounds competition which featured early-stage life sciences companies developing solutions related to COVID-19.
Ryan has successfully represented, including as lead counsel, multiple disabled veterans before the U.S. Court of Appeals for Veterans Claims. He also serves as a member of the Friends Board of the Legal Services of Northern Virginia.
2:19-cv-00209; 2:20-cv-00070, E.D. Tex., Judge Gilstrap
1:19-cv-01539, D. Del., Judge Stark
1:18-cv-00664, D. Del., Judge Andrews
1:17-cv-00414, D. Del., Judges Goldberg, Thynge
1:15-cv-01000, D. Del., Judge Andrews
1:13-cv-00707, S.D. Ohio, Judge Dlott
Represented Eli Lilly in a district court contempt proceeding enforcing a permanent injunction covering its Zyprexa® drug product.
1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa
The Hillman Group, Inc. v. KeyMe, LLC
2:19-cv-00209; 2:20-cv-00070, E.D. Tex., Judge Gilstrap
KeyMe, LLC v. The Hillman Group, Inc.
1:19-cv-01539, D. Del., Judge Stark
AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc.
1:18-cv-00664, D. Del., Judge Andrews
Shire ViroPharma Inc. v. CSL Behring LLC
Representing CSL Behring in a patent infringement suit against a competitor involving C1-INH biologic drugs for use in treating hereditary angioedema (HAE).
1:17-cv-00414, D. Del., Judges Goldberg, Thynge
AstraZeneca LP v. SigmaPharm Laboratories
Representing AstraZeneca in in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.
1:15-cv-01000, D. Del., Judge Andrews
The Hillman Group, Inc. v. Minute Key, Inc.
1:13-cv-00707, S.D. Ohio, Judge Dlott
Webinar
Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity
November 17, 2020
Webinar
Conference
2020 AdvanSE Life Sciences Virtual Conference 2020 AdvanSE Life Sciences Virtual Conference
November 9-13, 2020
Virtual
Webinar
Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation
October 16, 2019
Webinar
Articles
FDA Commissioner’s Statement on Plans for the Orange Book FDA Commissioner’s Statement on Plans for the Orange Book
March 9, 2019
FDA Flash! BlogIP FDA Blog
FDA Commissioner Statement about the Orange Book FDA Commissioner Statement about the Orange Book
February 7, 2019
Articles
Could the 'Dance' Already Be Over? ACA Repeal and Biosimilars Could the 'Dance' Already Be Over? ACA Repeal and Biosimilars
February 17, 2017
BNA's Life Sciences Law & Industry ReportPress Release
Finnegan Elevates Six Attorneys to Partner Finnegan Elevates Six Attorneys to Partner
January 4, 2021
Announcement
Best Lawyers Recognizes 21 Finnegan Attorneys Best Lawyers Recognizes 21 Finnegan Attorneys
August 28, 2020
Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.